Expert Interview
Discussing Surface Oncology’s CD39 and CD73 Pipeline in advanced solid tumors
Ticker(s): SURF, AZNAn oncologist with experience in treating advanced solid tumors, targeting anti-CD73 antibody and CD39.
Please tell us about your clinical experience. How many patients with advanced solid tumors do you see on a yearly basis? What is the standard of care, and what treatment is available for anti-CD73 antibody or CD39 activity?
Could you tell us more about the mechanism of action of NZV930 as a fully human anti-CD73 antibody that has been shown in preclinical studies to inhibit CD73 enzymatic activity, reduce levels of adenosine and increase the proliferation of T cell receptor-stimulated CD4+ T cells? And if possible, a comparison with Astra Zeneca’s oleclumab - anti-CD73 monoclonal antibody?
Could you also briefly discuss the recent results from AstraZeneca for its anti-CD73 candidate, where Imfinzi in combination with oleclumab reduced the risk of disease progression or death by 56%, and in combination with monalizumab by 35% vs Imfinzi alone in Stage III NSCLC patients following CRT. Also reported was the 10-month PFS rate stood at 64.8% for the durvalumab plus oleclumab combination and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.
What are your thoughts on the results for primary endpoint of confirmed ORR for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%)?
What’s your impression on Surface Oncology’s SRF617 - fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, the company touts its dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. Could you discuss this?
The company recently presented preliminary data from Phase 1 study of SRF617 CD39 inhibitor monotherapy and set a recommended Phase 2 dose of 1,400 mg. It was also reported on SRF617’s potential as a combination therapy, including an unconfirmed partial response in a patient with pancreatic cancer receiving second-line treatment with SRF617 in combination with gemcitabine/albumin-bound paclitaxel (Abraxane). Can you comment on what your impression is regarding the potential for the drug?
How big is the need for new drugs in this area of tumor targeting?
How likely are you to consider the company’s pipeline of oncology candidates, for your patients?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
